Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement).
Interpreting Haemonetics (HAE) International Revenue Trends
Review Haemonetics' (HAE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
Haemonetics Corporation ( HAE ) Q2 2026 Earnings Call November 6, 2025 8:00 AM EST Company Participants Olga Guyette - Senior Director of Investor Relations Christopher Simon - CEO, President & Director James D'Arecca - CFO, Executive VP & Financial Officer Conference Call Participants Rohin Patel - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.
Haemonetics (HAE) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.12 per share a year ago.
Understanding Haemonetics (HAE) Reliance on International Revenue
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.
